
US FDA approves Mirum's drug for rare bone disorder
The United States Food and Drug Administration has approved Mirum Pharmaceuticals' drug zilurgisertib, marketed under the brand name Atebrioz, to treat fibrodysplasia ossificans progressiva in patients aged twelve years and older. Announced on Friday, the once-daily oral medication is designed to treat the rare genetic disorder that causes bone to...








